Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)

Inclusion Criteria: * Patient who signed the informed consent, * Chronic stable ischemic cardiomyopathy for at least one month with a NYHA Class II-IV and/or -Angina pectoris CCS Class III or IV, * Not a candidate for revascularization by coronary artery by-pass surgery or angioplasty, * Left ventricular function ≤45%, * Presence of ischemia or myocardial viability on the myocardial perfusion imaging, * VO2 max≤ 20 ml/min/kg, * Optimal medical therapy, * Optimal interventional therapy (Implantable Cardiovertor Defibrillator, effort rehabilitation). Exclusion criteria: * Pregnancy or breastfeeding, * Acute coronary syndrome or myocardial infarction during the last 3 months, * Revascularization (PCI or CABG), or cardiac resynchronization during the last 3 months, * Further revascularization planned for the next 30 days, * LVEF \>45%, * Left intraventricular Thrombus and / or ventricular aneurysm detected by transthoracic echocardiography, * Wall thickness in the target region \<8 mm as determined by echocardiography, * Critical Limb Ischemia stages 3 or 4, * Inability to achieve a VO2 test, * Not feasible peripheral arterial access for percutaneous procedure, * Aortic stenosis (\<1cm²) or aortic insufficiency (\> 2 +), * Patients with transplanted organ, * Chronic renal failure with creatinemia ≥ 250 µmol/L, * Severe hepatic dysfunction, * Chronic atrial fibrillation, * Decompensated heart failure, * Uncontrolled Ventricular arrhythmias, * Indication of cardiac resynchronization by multisite pacemaker or cardiac resynchronization during the last 3 months, * Obesity preventing bone marrow aspiration or manual compression of the puncture area after bone marrow collection, * Active uncontrolled infection * Immuno-modulator treatment (ciclosporin, mycophenolate, mycophenolate mofetil, azathioprine, tacrolimus, anthracyclines, neupogen, hydrea, etanercept interferons, prednisolone, methylprednisolone, colchicine), * History of cancer in the last 5 years, * Hemopathy, hematopoietic disease, * Haemorrhagic syndrome, * Chronic or progressive disease that may alter the prognosis within 3 months, * Positive serologies for Human immunodeficiency virus (HIV1-2), HTLV-1 (human T-cell lymphotrophic virus) and 2, HBV (hepatitis B virus) or HCV (hepatitis B virus). * Allergic to xylocain.